TCF19 Promotes Cell Proliferation through Binding to the Histone H3K4me3 Mark

Mondal, Payel; Sen, Sabyasachi; Klein, Brianna J.; Tiwary, Niharika; Gadad, Shrikanth S.; Kutateladze, Tatiana G.; Roy, Siddhartha; Das, Chandrima

doi:10.1021/acs.biochem.9b00771

Cited by 25 publications

(23 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…37 Subsequently, we demonstrated that miR-1207-5p directly inhibited the expression of TCF19, a newly identified target of miR-1207-5p, that could play an oncogenic role in several cancers, such as colorectal cancer, 23 non-small cell lung cancer, 24 and liver cancer. 22,38 Consistent with the findings of previous studies, 22,38 we demonstrated that TCF19 promoted cell proliferation in HCC. Besides, we further showed the migratory capacities of liver cancer cells regulated by TCF19.…”

Section: Discussionsupporting

confidence: 91%

<p>LncRNA MIR194-2HG Promotes Cell Proliferation and Metastasis via Regulation of miR-1207-5p/TCF19/Wnt/β-Catenin Signaling in Liver Cancer</p>

Xu¹,

Zhu²,

Liu³

et al. 2020

OTT

View full text Add to dashboard Cite

LncRNAs play an important role in tumorigenesis and cancer progression in liver cancer. Although many lncRNAs have been reported, the role of MIR194-2HG and the underlying mechanism mediated by it are still largely unknown in HCC. This study aimed to investigate the biological role and mechanism of MIR194-2HG in liver cancer. Materials and Methods: The expression of MIR194-2HG was determined in liver cancer tissues and cells by RT-qPCR. The overall survival rate of MIR194-2HG was analyzed by Kaplan-Meier survival analysis. 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT), colony formation, and Transwell assays were carried out to detect cell migration and invasion. Western blotting was used to quantify the levels of all proteins. The regulatory mechanism of the MIR194-2HG/miR-1207-5p/TCF19 axis in liver cancer was investigated by dual-luciferase activity reporter assay, Kaplan-Meier survival analysis, and Western blotting. Results: MIR194-2HG was upregulated in liver cancer tissues and cell lines. Liver cancer patients with higher expression of MIR194-2HG revealed poor overall survival compared with those who had lower expression of MIR194-2HG. MIR194-2HG promoted the proliferation, migration, and invasion of HepG2 and Huh7 cells by acting as a ceRNA mechanism for the miR-1207-5p/TCF19 axis to activate the Wnt/β-catenin signaling pathway. Conclusion: MIR194-2HG acts in an oncogenic role and activates the Wnt/β-catenin signaling pathway via a miR-1207-5p/TCF19 axis-mediated mechanism, which provides a novel avenue for diagnostic or therapeutic interventions in liver cancer.

show abstract

Section: Discussionsupporting

confidence: 91%

<p>LncRNA MIR194-2HG Promotes Cell Proliferation and Metastasis via Regulation of miR-1207-5p/TCF19/Wnt/β-Catenin Signaling in Liver Cancer</p>

Xu¹,

Zhu²,

Liu³

et al. 2020

OTT

View full text Add to dashboard Cite

show abstract

“…There were no reports of the expression level of THBD in brain tumors, our study showed that THBD was highly expressed in GBM patients, and patients with different expression levels had inequable prognosis. Finally, several studies had found that in non-small cell lung cancer, hepatocellular carcinoma, and colorectal cancer TCF19 (transcription factor 19) could promote cell proliferation and increase tumor invasiveness through some pathways, but there were no reports about its role in GBM [33][34][35][36]. Our study found that TCF19 was highly expressed in GBM patients, and patients with different expression levels also had inequable prognosis.…”

Section: Discussionmentioning

confidence: 54%

Identification of novel genes associated with diagnosis and prognosis in glioblastoma

Cai

Tang

et al. 2020

Preprint

View full text Add to dashboard Cite

Background: Glioblastoma (GBM) is the most lethal primary brain cancer and its survival rate is very low. Comprehensive genomic characteristics and high degree of heterogeneity of GBM are main causes that contribute to the absence of effective therapeutic targets and prognostic markers and eventual treatment failures. Here, Gene set enrichment analysis (GSEA) was used to explore comprehensive genomic characteristics and high degree of heterogeneity of GBM. Our study will help explain potential tumorigenesis mechanism and contribute to development of targeted therapeutics and prediction of patient prognosis.Methods: Gene expression profile of GSE50161 was downloaded from Gene Expression Omnibus (GEO) database and GSEA was performed to evaluate the microarray data at level of gene sets of GO, KEGG and hallmark of Molecular Signatures Database (MSigDB). Core enrichments of selected hallmark gene sets were applied for clinical prognosis verification in Gene Expression Profiling Interactive Analysis (GEPIA). Genes associated with significant overall survival (OS) and unreported before were recognized as novel; the expression levels of novel genes in GBM samples and every novel gene between normal brain and GBM samples were compared. Receiver operating characteristic (ROC) and Pearson correlation analysis were also performed to evaluate the diagnostic biomarkers of GBM and correlations among novel genes respectively.Results: We obtained 511 and 494 GO gene sets, 12 and 10 KEGG gene sets, and 2 and 8 hallmark gene sets in normal and GBM samples respectively. Five novel genes SERPINA5, TENM2, ARAP3, THBD, TCF19 associated with GBM prognosis were selected and four novel genes SERPINA5, TENM2, ARAP3, TCF19 performed well for GBM diagnosis prediction were obtained. In addition, we also found that four novel genes SERPINA5, ARAP3, THBD, TCF19 that high expressed in GBM samples were all positively correlated with each other and correlation between ARAP3 and TCF19 was the strongest.Conclusions: Our study will help deeper understand the molecular heterogeneity and develop of targeted therapeutics of GBM; five novel related to prognosis genes (of which four are also related to diagnosis) may be applied to more accurate clinical decision-making process.

show abstract

“…Similar to MYBL1, TCF19 is required for progression from G1 to S phase of the cell cycle [43]. Zeng et al [44] show the TCF19 gene is involved in cell proliferation and tumorigenesis in hepatocellular carcinoma, and Mondal et al [45] show TCF19 is necessary for both proliferation and survival of pancreatic tumor cells. siRNA-mediated knockdown of Tcf19 in the INS-1 insulinoma cell line, led to a reduction in numerous G1 to M phase cell cycle genes [17] further validating the involvement of TCF19 in cell cycle signaling.…”

Section: Discussionmentioning

confidence: 99%

MYBL1 Knockdown in a Triple Negative Breast Cancer Line: Evidence of Down-Regulation of MYBL2, TCF19 and KIF18b Expression

A¹,

Abraham²,

Abdulrahman³

et al. 2021

austinjcancerclinres

View full text Add to dashboard Cite

Purpose: The MYBL1 gene is a strong transcriptional activator, associated with cell cycle signaling and differentiation. Data show the gene is overexpressed in triple negative breast cancers. Considering the possibility that MYBL1 might be involved in events associated with the pathogenesis of these cancers, we sought to identify genes associated with MYBL1 expression in triple negative breast cancer. Methods: shRNA lentiviral knockdown was used to down-regulate the MYBL1 gene. Microarray analyses were used to identify genes either directly or indirectly affected by targeting MYBL1 knockdown. Data analyses was performed utilizing Affymetrix TAC 4.0, Chip X transcription factor analyses, Target Scan miRNA analyses, and STRING analyses was used to determine protein: protein interaction and pathway analyses. Web Gestalt and Gene Ontology were used to determine pathway and gene-set enrichments. Publicly available patient and cell line datasets were retrieved and processed using resources available in Gene Expression Omnibus and Oncomine. The polymerase chain reaction and western analyses were used to determine transcript and protein levels, respectively. Results: Knockdown of MYBL1 in a triple negative breast cell line led to down-regulation of MYBL2, TCF19, KIF18b along with an enrichment of cell cycle signaling genes. Gene expression analyses show that MYBL1, MYBL2, TCF19 and KIF18b display a similar pattern of expression in breast cell lines and many of the archival patient datasets examined. Conclusion: TNBC is a heterogeneous subtype, so these data suggest that cancers that over-express MYBL1, express MYBL2, TCF19 and KIF18b. Bioinformatic analyses suggest MYBL1 regulates MYBL2 which leads to regulation of TCF19 and KIF18b.

show abstract

TCF19 Promotes Cell Proliferation through Binding to the Histone H3K4me3 Mark

Cited by 25 publications

References 30 publications

<p>LncRNA MIR194-2HG Promotes Cell Proliferation and Metastasis via Regulation of miR-1207-5p/TCF19/Wnt/β-Catenin Signaling in Liver Cancer</p>

<p>LncRNA MIR194-2HG Promotes Cell Proliferation and Metastasis via Regulation of miR-1207-5p/TCF19/Wnt/β-Catenin Signaling in Liver Cancer</p>

Identification of novel genes associated with diagnosis and prognosis in glioblastoma

MYBL1 Knockdown in a Triple Negative Breast Cancer Line: Evidence of Down-Regulation of MYBL2, TCF19 and KIF18b Expression

Contact Info

Product

Resources

About